Tapinarof effective for AD in patients as young as 2 years.

The article focuses on the efficacy of tapinarof cream, an aryl hydrocarbon receptor agonist, for treating atopic dermatitis (AD) in both adults and children as young as 2 years old, based on results from two phase 3 trials. It discusses that tapinarof demonstrated high effectiveness, safety and tolerability; significant improvements in itch control; and a potential alternative to topical corticosteroids for AD management.